

Consolidated Financial Results for the First Quarter of FY2019

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

| | FY2018 Q1 | | FY2019 Q1 | | YoY |
|--|---------------------|--------|---------------------|--------|--------|
| | Apr. 2018-Jun. 2018 | | Apr. 2019-Jun. 2019 | | |
| | Millions of Yen | Ratio | Millions of Yen | Ratio | |
| Net Sales | 12,761 | 100.0% | 13,991 | 100.0% | 9.6% |
| Cost of Sales | 7,449 | 58.4% | 7,361 | 52.6% | -1.2% |
| Gross Profit | 5,311 | 41.6% | 6,629 | 47.4% | 24.8% |
| Selling, General and Administrative Expenses | 4,086 | 32.0% | 5,791 | 41.4% | 41.7% |
| Operating Income | 1,217 | 9.5% | 837 | 6.0% | -31.2% |
| Profit Attributable to Owners of Parent | 1,062 | 8.3% | 563 | 4.0% | -47.0% |

Forecast of Consolidated Financial Results for the FY2019

| | FY2018 Actual | | FY2019 Forecast | | YoY |
|---|---------------------|--------|---------------------|--------|--------|
| | Apr. 2018-Mar. 2019 | | Apr. 2019-Mar. 2020 | | |
| | Millions of Yen | Ratio | Millions of Yen | Ratio | |
| Net Sales | 46,706 | 100.0% | 53,000 | 100.0% | 13.5% |
| Operating Income | 1,782 | 3.8% | 2,000 | 3.8% | 12.2% |
| Profit Attributable to Owners of Parent | 1,744 | 3.7% | 1,000 | 1.9% | -42.7% |

Sales of Main Products

(Billions of yen)

| Therapeutic Category | Products | FY2018 Q1 Actual | FY2019 Q1 Actual | FY2019 Forecast |
|---|--------------|------------------|------------------|-----------------|
| Antihypertensive agent | CANDESARTAN* | 3.17 | 3.76 | 13.60 |
| Thyroid hormone | THYRADIN | 1.98 | 1.79 | 6.98 |
| LH-RH derivative | LEUPRORELIN | 1.01 | 1.29 | 4.52 |
| Poorly absorbable rifamycin antimicrobial agent | RIFXIMA | 0.54 | 0.91 | 3.89 |
| Dysmenorrhea agent | FREWELL | 0.00 | 0.48 | 2.01 |
| Antihypertensive agent | AMLODIPINE | 0.36 | 0.44 | 1.53 |
| Hyperlipidemic agent | LIPDIL | 0.63 | 0.40 | 1.21 |
| Prostate cancer therapeutic agent | BICALUTAMIDE | 0.32 | 0.39 | 1.06 |
| Antithyroid agent | MERCAZOLE | 0.31 | 0.36 | 1.34 |
| GnRH antagonist | RELUMINA | - | 0.31 | 1.98 |

*Including CANDESARTAN formulation's sales